Dynavax Technologies Corporation  

(Public, NASDAQ:DVAX)   Watch this stock  
Find more results for DVAX
16.61
+0.32 (1.96%)
Real-time:   10:21AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.26 - 16.63
52 week 12.84 - 32.49
Open 16.27
Vol / Avg. 19,241.00/573,737.00
Mkt cap 640.22M
P/E     -
Div/yield     -
EPS -2.79
Shares 38.50M
Beta 2.50
Inst. own 86%
Nov 3, 2016
Q3 2016 Dynavax Technologies Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 5, 2016
Q2 2016 Dynavax Technologies Corp Earnings Release
Jun 15, 2016
Dynavax Technologies Corp at William Blair Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -1095.05% -2636.89%
Operating margin -1105.18% -2635.65%
EBITD margin - -2517.33%
Return on average assets -65.09% -60.18%
Return on average equity -76.69% -74.28%
Employees 234 -
CDP Score - -

Address

2929 7th St Ste 100
BERKELEY, CA 94710-2753
United States - Map
+1-510-8485100 (Phone)
+1-510-8481327 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Officers and directors

Arnold L. Oronsky Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Eddie Gray Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Michael S. Ostrach Principal Financial Officer, Vice President, General Counsel, Chief Business Officer
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Coffman Ph.D. Senior Vice President, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
David F. Novack Senior Vice President - Operations and Quality
Age: 53
Bio & Compensation  - Reuters
David Louis Johnson Chief Accounting Officer, Vice President
Age: 57
Bio & Compensation  - Reuters
Robert Janssen M.D. Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 58
Bio & Compensation  - Reuters
Natale S. Ricciardi Director
Age: 67
Bio & Compensation  - Reuters
Francis R Cano Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters